Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Just over a year after striking an obesity deal with Novo Nordisk, an SEC filing shows Flagship Pioneering spinout Omega ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

President Prabowo Subianto’s universal free meals programme is well-intentioned, but it would be more effective if done in ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Indian athletes and fitness influencers are stepping up to support Prime Minister Narendra Modi's clarion call to combat ...

If Robert F. Kennedy Jr. and the Trump administration want to make America healthy again, they should let Medicare cover weight loss drugs.

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...